Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Friday, July 20, 2018 · 456,062,029 Articles · 3+ Million Readers

Global Nuclear Medicine/Radiopharmaceuticals Market, 2022 - Market is expected to reach $9,275.3

/EIN News/ -- Dublin, July 27, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast to 2022" report to their offering.

The global nuclear medicine/radiopharmaceutical market is expected to reach $9,275.3 million by 2022

Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.

Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The nuclear medicine market end-users include medical, academic research laboratories and industries. The end-users by medical further segmented into hospitals and diagnostic centers.

The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market.

In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market.

The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Description
2.3 Markets Covered
2.4 Stakeholders
2.5 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.4 Problem Areas
3.5 Winning Imperatives
3.6 Regulatory Guidelines
3.7 Reimbursement Scenario & Challenges
3.8 Patent Trends
3.9 Supply Chain Analysis
3.10 List Of Potential New Reactors
3.11 Porter's Five Force Analysis
3.12 Market Share Analysis By Major Players

4 Radiopharmaceuticals By Type
4.1 Introduction
4.2 Diagnostics
4.3 Therapeutics

5 Global Nuclear Medicine Market By End-Users
5.1 Introduction
5.2 Medical
5.3 Academic Research Laboratories
5.4 Industries

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.3 Stable Isotopes Market, By Isotopes
6.4 Stable Isotopes Market, By Applications
6.5 Stable Isotopes Market, By Geography

7 Regional Analysis
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Rest Of The World

8 Competitive Landscape
8.1 Introduction
8.2 New Product Launches
8.3 Agreements, Partnership, Collaboration & Joint Ventures
8.4 Approvals
8.5 Expansions
8.6 Mergers & Acquisitions
8.7 Other Developments

9 Major Player Profiles
9.1 Bayer Healthcare
9.2 Cardinal Health Inc.
9.3 Cambridge Isotope Laboratories Inc.
9.4 Ge Healthcare
9.5 Iba Group
9.6 Isotec Inc
9.7 Lantheus Medical Imaging Inc.
9.8 Mallinckrodt Plc
9.9 Nordion Inc
9.10 Ntp Radioisotopes Soc Ltd
9.11 Siemens Healthcare
9.12 Taiyo Nippon Sanso Corporation

Companies Mentioned

- Ablynx Nv
- Abx Gmbh
- Actinium Pharmaceuticals, Inc
- Advanced Accelerator Applications
- Advanced Medical Isotope Corporation
- Affibody Ab
- Algeta Asa
- Aptuit
- Areva Med
- Arronax
- Auspex Pharmaceuticals
- Bard Medicals
- Bavarian Nordic
- Bayer Healthcare
- Best Medical International, Inc
- Bio Analytical Research Corporation Laboratories
- Bio-Nucleonics,Inc
- Bracco Diagnostics Incs
- Btg International Ltd
- Bv Cyclotron Vu
- Cambridge Isotope Laboratories Inc.
- Cardinal Health Inc.
- Cellectar Biosciences
- Centre For Probe Development And Commercialization
- China Isotope Corporation
- Clarity'S Pharmaceuticals
- Coqui Pharmaceuticals
- Cortecnet
- Cp Medical
- Digirad Corporation
- Draximage Inc.
- Eckert & Ziegler Strahlen
- Eden Radioisotopes Llc
- Eli Lilly & Co
- Eurisotop
- Fujifilm Corporation
- Ge Healthcare
- Huayi Isotopes Co
- Iba Group
- Ibt-Bebig
- Idb Holland Bv
- Immunomedics
- Industrial Nuclear Company
- International Isotopes Inc.
- Invap S.E
- Iso Ray Medical Inc
- Iso Therapeutics Group, Llc
- Iso-Analytical Ltd
- Isoaid Llc
- Isoflex Isotope
- Isorad Ltd
- Isotec Inc
- Isotope Technologies Garching
- Ithemba Labs
- Joint Stock Company Isotope
- Lantheus Medical Imaging Inc
- Linde Group
- Mallinckrodt Plc
- Medi-Physics, Inc
- Medical Isotopes, Inc
- Mediso Medical Imaging Systems
- Memorial Sloan Kettering Cancer Center
- Navidea Biopharmaceuticals Inc
- Nihon Medi Physics Co Ltd
- Nordion Inc.
- Northstar Medical Technologies
- Ntp Radioisotopes Soc Ltd
- Octreopharm Sciences Gmbh
- Ostuka Pharmaceuticals Co Ltd
- Pars Isotope
- Peregrine Pharmaceuticals, Inc
- Perkin Elmer
- Perma-Fix Medical Sa
- Petnet Solution
- Philips Health Care
- Positron Corporation
- Radiomedix, Inc.
- Rotem Medical
- Royal Philips Electronics
- Sanofi
- Sercon Australia Pvt Ltd
- Sercon Ltd
- Shangai Research Institute Of Chemical Industry
- Shine Medical Technologies, Inc
- Siemens Healthcare
- Sievert
- Sirtex
- Source Production And Equipment Company+F191
- Spectrum Pharmaceuticals, Inc
- Spepharm Ag
- Stb Isotope Germany Gmbh
- Sterigenics International
- Steripet
- Tayyo Nippon Sanso Corporation
- Theragenics Corporation
- Thermo Fisher Scientific
- Toshiba Medical Systems Corporation
- Tracerco
- Trigon Biotechnology Inc
- Urenco
- Westinghouse Electric Company
- Zevacor Molecular

For more information visit

                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Sector: Nuclear Medicine and Radiopharmacology

Primary Logo

Powered by EIN News